SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection

被引：52
|
作者：
Bell, Robert M. [1 ]
Yellon, Derek M. [1 ]
机构：
[1] UCL, Hatter Cardiovasc Inst, London WC1E 6HX, England
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2018年 / 6卷 / 06期
关键词：
OUTCOMES; EMPAGLIFLOZIN;
D O I：
10.1016/S2213-8587(17)30314-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：435 / 437
页数：4
相关论文
共 50 条
  • [41] Ketoacidosis with SGLT2 Inhibitors
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1471): : 94 - 94
  • [42] SGLT2 inhibitors and cardioprotection
    Chen, S.
    Wang, Q.
    Christodoulou, A.
    Mylonos, N.
    Bakker, D.
    Wakker, V.
    Hollmann, M. W.
    Weber, N. C.
    Coronel, R.
    Christoffels, V.
    Andreadou, I.
    Zuurbier, C. J.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2023, 53
  • [43] SGLT2 inhibitors: oral antidiabetic agent and/or treatment in the cardiovascular prevention and/or kidney protection? Place to debate
    Krempf, M.
    ARCHIVES OF CARDIOVASCULAR DISEASES SUPPLEMENTS, 2019, 11 : S23 - S29
  • [44] SGLT2 inhibitors: are they safe?
    Filippas-Ntekouan, Sebastian
    Filippatos, Theodosios D.
    Elisaf, Moses S.
    POSTGRADUATE MEDICINE, 2018, 130 (01) : 72 - 82
  • [45] SGLT2 inhibitors and protection against pancreatic beta cell failure
    Asahara, Shun-ichiro
    Ogawa, Wataru
    DIABETOLOGY INTERNATIONAL, 2019, 10 (01) : 1 - 2
  • [46] SGLT2 inhibitors and protection against pancreatic beta cell failure
    Shun-ichiro Asahara
    Wataru Ogawa
    Diabetology International, 2019, 10 : 1 - 2
  • [47] Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials
    Silva-Cardoso, Jose
    Sheikh, Omar
    Nashawi, Mouhamed
    Pham, Son
    Gallegos, Kelly M.
    Dinkha, Laith R.
    Chilton, Robert J.
    JOURNAL OF DIABETES, 2020, 12 (04) : 279 - 293
  • [48] SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback
    Upadhyay, Ashish
    KIDNEY360, 2024, 5 (05): : 771 - 782
  • [49] Progenitor Cell Function and Cardiovascular Remodelling Induced by SGLT2 Inhibitors
    Stougiannou, Theodora M.
    Christodoulou, Konstantinos C.
    Koufakis, Theocharis
    Mitropoulos, Fotios
    Mikroulis, Dimitrios
    Mazer, Cyril David
    Karangelis, Dimos
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2024, 29 (04):
  • [50] Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors
    Vargas-Delgado, Ariana P.
    Arteaga Herrera, Estefania
    Tumbaco Mite, Cesar
    Delgado Cedeno, Patricia
    Van Loon, Maria Cristina
    Badimon, Juan J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
12345